INCY Stock Overview
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$66.61|
|52 Week High||US$84.86|
|52 Week Low||US$61.91|
|1 Month Change||-4.79%|
|3 Month Change||-14.24%|
|1 Year Change||-3.16%|
|3 Year Change||-11.04%|
|5 Year Change||-41.35%|
|Change since IPO||3,452.53%|
Recent News & Updates
Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
Summary Biotech has pulled back sharply after a summer rebound, but the niche continues to outperform the S&P 500. One mid-sized biotech company is looking forward to better earnings ahead with a decent pipeline of oncology and dermatology products. With an attractive valuation, the chart also gives the bulls reason for optimism. Biotech stocks were beaten down during the first several months of the year. The SPDR S&P Biotech ETF (XBI) was more than cut in half from this time a year ago to its May low, sharply underperforming the broad stock market. Since early May, though, risky biotech shares have managed to stage an absolute and relative rally. Despite a sharp correction off its August peak, as XBI plummeted from $95 to under $80 today, the ETF has still returned more than 25% since its 2022 low. It’s also bullish that biotech equities bottomed ahead of the S&P 500. One SPX-listed stock features an optimistic earnings outlook with an intriguing chart setup. Biotech Bounces Off Q2 Lows, Alpha vs. S&P 500 Since May Stockcharts.com According to Bank of America Global Research, Incyte Corporation (INCY) is a biotechnology company developing oral and topical treatments for oncology and dermatology indications. The company's main asset is Jakafi for MF and PV. INCY's Opzelura (ruxolitinib cream) was recently approved for the treatment of AD and impending vitiligo sNDA submission. In addition, INCY has a broad early clinical oncology pipeline. There’s upside potential for INCY’s profits through its Jakafi revenue and late-stage dermatology program developments. Downside risks could include weaker than expected Jakafi and Opzelura revenue estimates as well as poor clinical trials. The Delaware-based $15.1 billion market cap Biotechnology industry company within the Health Care sector trades at a near-market multiple of 15.7 times trailing 12-month GAAP earnings and does not pay a dividend, according to The Wall Street Journal. On valuation, BofA sees significant earnings upside potential through 2024 after a sharp dip this year. Moreover, the Bloomberg consensus forecast shows positive per-share profits in the years ahead, but not quite as sanguine as BofA. While no dividend is anticipated, its EV/EBITDA multiple is seen as dropping and free cash flow looks to be on the rise. Seeking Alpha rates its profitability with an A+ despite just a B- growth rating. It's operating price-to-earning ratio should retreat if the share remains stable. Incyte Earnings, Valuation, And Free Cash Flow Forecasts BofA Global Research
Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia
Incyte's (NASDAQ:INCY) drug Pemazyre to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. The decision to approve for the indication had been made on the basis of overall response rate and duration of response and a continued approval depends on verification and description of benefit in confirmatory trials. The drug has also been approved in the United States, Europe, Great Britain, Canada and Japan. Pemazyre is not yet reimbursed in Australia, it is currently being made available to eligible patients via a co-pay access program. In the primary analysis of 108 patients enrolled in the trial, treatment with the drug resulted in an objective response rate of 37% with 3.7% of patients having a confirmed complete response and 33.3% having a confirmed partial response.
Incyte wins approval of Pemazyre for rare blood cancer
The US FDA has approved Incyte's (NASDAQ:INCY) Pemazyre (pemigatinib) for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. The selective fibroblast growth factor receptor (FGFR) inhibitor was approved based on the phase 2 FIGHT-203 study, a single-arm trial in 28 patients. Results showed that with patients in the chronic phase in the marrow with or without extramedullary disease, the complete response rate ("CR") was 78%. The median time to response of CR was 104 days. Pemazyre gained it first approval in 2020 for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion. Seeking Alpha contributor Walter Zelezniak Jr, who has a buy rating on Incyte (INCY), provides a technical analysis of the stock.
|INCY||US Biotechs||US Market|
Return vs Industry: INCY exceeded the US Biotechs industry which returned -24.2% over the past year.
Return vs Market: INCY exceeded the US Market which returned -20.3% over the past year.
|INCY Average Weekly Movement||3.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: INCY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: INCY's weekly volatility (4%) has been stable over the past year.
About the Company
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic.
Incyte Fundamentals Summary
|INCY fundamental statistics|
Is INCY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INCY income statement (TTM)|
|Cost of Revenue||US$1.66b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||4.25|
|Net Profit Margin||28.46%|
How did INCY perform over the long term?See historical performance and comparison
Is INCY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INCY?
Other financial metrics that can be useful for relative valuation.
|What is INCY's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does INCY's PE Ratio compare to its peers?
|INCY PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
HZNP Horizon Therapeutics
UTHR United Therapeutics
Price-To-Earnings vs Peers: INCY is good value based on its Price-To-Earnings Ratio (15.7x) compared to the peer average (17.8x).
Price to Earnings Ratio vs Industry
How does INCY's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: INCY is expensive based on its Price-To-Earnings Ratio (15.7x) compared to the US Biotechs industry average (15.1x)
Price to Earnings Ratio vs Fair Ratio
What is INCY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15.7x|
|Fair PE Ratio||30x|
Price-To-Earnings vs Fair Ratio: INCY is good value based on its Price-To-Earnings Ratio (15.7x) compared to the estimated Fair Price-To-Earnings Ratio (30x).
Share Price vs Fair Value
What is the Fair Price of INCY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: INCY ($66.61) is trading below our estimate of fair value ($317.1)
Significantly Below Fair Value: INCY is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Incyte forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INCY's forecast earnings growth (30% per year) is above the savings rate (1.9%).
Earnings vs Market: INCY's earnings (30% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: INCY's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INCY's revenue (12.6% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: INCY's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INCY's Return on Equity is forecast to be high in 3 years time (27.7%)
Discover growth companies
How has Incyte performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INCY has a high level of non-cash earnings.
Growing Profit Margin: INCY's current net profit margins (28.5%) are higher than last year (12.4%).
Past Earnings Growth Analysis
Earnings Trend: INCY has become profitable over the past 5 years, growing earnings by 50% per year.
Accelerating Growth: INCY's earnings growth over the past year (179.9%) exceeds its 5-year average (50% per year).
Earnings vs Industry: INCY earnings growth over the past year (179.9%) exceeded the Biotechs industry 29.2%.
Return on Equity
High ROE: INCY's Return on Equity (23.1%) is considered high.
Discover strong past performing companies
How is Incyte's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: INCY's short term assets ($3.6B) exceed its short term liabilities ($926.7M).
Long Term Liabilities: INCY's short term assets ($3.6B) exceed its long term liabilities ($307.3M).
Debt to Equity History and Analysis
Debt Level: INCY is debt free.
Reducing Debt: INCY has no debt compared to 5 years ago when its debt to equity ratio was 2.3%.
Debt Coverage: INCY has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INCY has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Incyte current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Incyte Dividend Yield vs Market|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Incyte)||0%|
Notable Dividend: Unable to evaluate INCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INCY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INCY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INCY's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INCY has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Herve Hoppenot (62 yo)
Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and President since January 13, 2014. Mr. Hoppenot served as the Chief Commerci...
CEO Compensation Analysis
|Herve Hoppenot's Compensation vs Incyte Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$14m||US$1m|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$16m||US$1m|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$15m||US$1m|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$9m||US$996k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$16m||US$967k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$12m||US$938k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$6m||US$899k|
Compensation vs Market: Herve's total compensation ($USD14.44M) is about average for companies of similar size in the US market ($USD13.03M).
Compensation vs Earnings: Herve's compensation has been consistent with company performance over the past year.
Experienced Management: INCY's management team is seasoned and experienced (6.5 years average tenure).
Experienced Board: INCY's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|10 Mar 22||BuyUS$28,107,770||Baker Bros. Advisors LP||Company||389,080||US$73.31|
|22 Feb 22||BuyUS$35,734,890||Baker Bros. Advisors LP||Company||525,804||US$68.43|
|14 Feb 22||BuyUS$106,952,404||Baker Bros. Advisors LP||Company||1,598,374||US$67.54|
|17 Dec 21||BuyUS$115,558,900||Baker Bros. Advisors LP||Company||1,595,519||US$72.91|
|Owner Type||Number of Shares||Ownership Percentage|
|State or Government||79,952||0.04%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Incyte Corporation's employee growth, exchange listings and data sources
- Name: Incyte Corporation
- Ticker: INCY
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$14.816b
- Shares outstanding: 222.43m
- Website: https://www.incyte.com
Number of Employees
- Incyte Corporation
- 1801 Augustine Cut-Off
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INCY||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Nov 1993|
|ICY||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 1993|
|0J9P||LSE (London Stock Exchange)||Yes||Common Shares||GB||USD||Nov 1993|
|ICY||ETLX (Eurotlx)||Yes||Common Shares||IT||EUR||Nov 1993|
|INCY *||BMV (Bolsa Mexicana de Valores)||Yes||Common Shares||MX||MXN||Nov 1993|
|I1NC34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 2 REPR 1 COM||BR||BRL||Jan 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.